Retatrutide is currently an investigational triple-hormone receptor agonist being developed by Eli Lilly and Company targeting GLP-1 GIP and glucagon

What Is Retatrutide UK Retatrutide UK is becoming an increasingly discussed topic among people interested in emerging weight-management treatments. Retatrutide